The splice forms of vascular endothelial growth factor (VEGF) differ in biological properties such as the receptor types that they recognize and their interaction with heparan sulfate proteoglycans. We have identified a new VEGF mRNA splice form encoding a VEGF species containing 162 amino acids (VEGF 162 ) in human A431 ovarian carcinoma cells. This novel mRNA contains the peptides encoded by exons 1-5, 6A, 6B, and 8 of the VEGF gene. Recombinant VEGF 162 is biologically active. It induces proliferation of endothelial cells in vitro and angiogenesis in vivo as determined by the alginate bead assay. VEGF 162 binds less efficiently than VEGF 145 but more efficiently than VEGF 165 to a natural basement membrane produced by corneal endothelial cells. VEGF 138 , an artificial VEGF form that contains exon 6B but lacks exons 6A and 7, did not bind to this basement membrane at all, indicating that exon 6B probably interferes with the interaction of exon 6A with heparin and heparan sulfate proteoglycans.
The various forms of vascular endothelial growth factor (VEGF) 1 are generated by alternative splicing from a single gene (1) (2) (3) (4) . The domains encoded by exons 1-5 of the VEGF gene contain information required for the recognition of the tyrosine kinase VEGF receptors 1 (flt-1) and 2 (KDR/flk-1) (5) and are present in all the VEGF splice forms. Most VEGF splice forms are distinguished by the presence or absence of the peptides encoded by exons 6 and 7 of the VEGF gene that code for two independent heparin-binding domains. VEGF 121 lacks both exons and does not bind to heparin. VEGF 165 contains the exon 7-encoded peptide, VEGF 145 contains the peptide encoded by exon 6A, and VEGF 189 contains both exon 6A and exon 7 (3, 6 -8) . VEGF 206 has a structure similar to that of VEGF 189 , except that it contains both exons 6A and 6B of the VEGF gene. However, the contribution of exon 6B to the biological properties of VEGF 206 has not been studied. The amino acids encoded by exon 8 are present in most of the VEGF splice forms. However, it was recently found that in the novel VEGF form VEGF 165b , the 6 amino acids encoded by exon 8 are replaced by 6 amino acids derived from a putative ninth exon to yield a VEGF form that probably inhibits angiogenesis (9) . In another recently described VEGF splice form, exon 8 is completely truncated to generate a 148-amino acid form (10) . In addition, it was recently found that VEGF forms possessing an extended N termini of unknown function also exist (11) .
Most VEGF isoforms induce proliferation of vascular endothelial cells, induce angiogenesis, and cause permeabilization of blood vessels (8) . Recently, certain differences between some common VEGF splice forms have been reported. The neuropilin-1 and neuropilin-2 receptors function as receptors for axon guidance factors belonging to the semaphorin family (12, 13) . It was found that both neuropilins also function as VEGF receptors that differentiate between various forms of VEGF (14, 15) . Thus, VEGF 121 cannot bind to either of the neuropilins, whereas VEGF 165 binds efficiently to both receptors, and VEGF 145 binds well to neuropilin-2 but not to neuropilin-1 (16) . Such differences are also reflected in the functional properties of the VEGF splice forms. It was found that mice expressing only VEGF 121 do not develop properly (17, 18) because the heparan sulfate-binding VEGF forms are required for correct branching of blood vessels during development (19) . Likewise, mice expressing only VEGF 189 display impaired arterial development (17) , suggesting that each VEGF form possesses specific characteristics and that the various VEGF forms complement each other to achieve a balanced angiogenic response.
Exon 6B was first identified in VEGF 206 (Fig. 1C ), but the effect of exon 6B on the biological properties of VEGF 206 had not been studied because VEGF 206 , like VEGF 189 , is not secreted into the medium of cells that produce these VEGF forms and is thus difficult to isolate and characterize. We report here the identification of a new exon 6B-containing form of VEGF expressed by A431 ovarian carcinoma cells. This VEGF form is 162 amino acids long (VEGF 162 ). In this work, we have characterized the properties of VEGF 162 and compared them with those of the closely related VEGF 145 and those of VEGF 138 , an artificial exon 6B-containing VEGF form.
EXPERIMENTAL PROCEDURES
Materials-Human recombinant VEGF 165 was purified from Sf-9 insect cells as described previously (20) . The pDCHIP11 plasmid (containing the DHFR minigene) was kindly provided by Dr. Lawrence Chasin (Columbia University, New York, NY) (21) . Rabbit polyclonal antibody directed against VEGF was produced in our laboratory as described previously (20) . Monoclonal anti-VEGF antibodies (V4758), peroxidase-conjugated anti-rabbit IgG antibodies, and alkaline phosphatase-conjugated anti-rabbit IgG antibodies were purchased from Sigma. The EZ-ECL kit was from Biological Industries Inc. (Beth Haemek, Israel). Heparin-Sepharose was purchased from Pharmacia Corporation. Tissue culture plasticware was from Corning. Tissue culture media were obtained from Invitrogen. Other tissue culture reagents were from Biological Industries Inc.
Detection of VEGF 162 mRNA in Cells-Total mRNA was prepared from A431 human ovarian carcinoma cells. Complementary DNA was synthesized from 5 g of total RNA using Moloney murine leukemia virus reverse transcriptase (Promega). A specific oligonucleotide derived from the 3Ј-untranslated region of VEGF mRNA (nucleotides 908 -931, GGGTGTGTCTACAGGAATCCCAG) was used as a primer. The reaction was carried out for 1 h at 37°C and for 30 min at 42°C, and the enzyme was then inactivated by a 10-min incubation at 90°C. PCR amplification was carried out in the presence of 5 units of Extaq Taq polymerase (Takara), 1 mM of each deoxynucleotide triphosphate, and 20 pmol of each primer. The oligonucleotides used as primers for the PCR reaction were CGGGATCCGAAACCATGAACTTTCTGC, corresponding to the first 9 N-terminal amino acids of the VEGF coding region, and CTTCCGGGCTCGGTGATTTAGCAG, corresponding to a sequence from the 3Ј-untranslated region of human VEGF (nucleotides 867-891). Each of the 30 amplification cycles consisted of a 40-s incubation at 94°C, a 1.5-min incubation at 63°C, and a 1.5-min incubation at 72°C.
The PCR products were precipitated, and an additional stage of nested PCR was performed, using internal primers specific for VEGF 162 : CGAATTCTGCCTTGCTGCTCTACCTCCACCAT, corresponding to amino acids 17-25 of the VEGF coding region, and GCT-TGTCACATTGGGGGCCA, corresponding to amino acids 184 -190 of VEGF 162 , located at the junction between exons 6B and 8 of the VEGF gene. The same amplification protocol was used for this step. However, the annealing temperature was raised to 68°C to exclude nonspecific products as much as possible.
Construction of VEGF 138 -and VEGF 162 -encoding Expression Vectors and Production of Recombinant VEGF 162 -The VEGF 162 cDNA was subcloned into the EcoRI site of the PECE expression vector (22) . The PECE/VEGF 162 vector was transfected into DG44 Chinese hamster ovary cells (CHO DHFRϪ cells) (23), along with the pDCHIP11 plasmid, which contains the DHFR minigene (21) . Cells were selected using minimum Eagle's medium ␣ lacking nucleosides. Increasing concentrations of methotrexate were used to amplify the VEGF 162 cDNA to enhance VEGF 162 production. The maximal concentration of methotrexate used was 100 nM. The concentrations of VEGF 162 in the conditioned medium of VEGF 162 -producing cells were assessed using anti-VEGF antibodies.
To partially purify the VEGF 162 protein, serum-free conditioned medium was applied to a heparin-Sepharose column. The column was pre-equilibrated with wash buffer (10 mM Tris, pH 7.5, 150 mM NaCl). The conditioned medium was loaded on this column. The column was then washed extensively with wash buffer and then washed with wash buffer containing 250 mM NaCl. Elution was performed with the same buffer containing 800 mM NaCl. This procedure was almost identical to the procedure used for the purification of VEGF 145 (4) .
To obtain a cDNA encoding VEGF 138 , we amplified the VEGF 145 cDNA by PCR using the 3Ј primer 5Ј-CGGGATCCTCACCGCCTCGG-CTTGTCACATTGGGGGCCAGGGAGGCTCCAGGGCATTAGACAGC-AGCGGGCACCAACGTACTTTTCTTGTCTTGCTCT-3Ј containing the entire exon 8 sequence fused to exon 6B and the last 17 bp of exon 5. The 5Ј primer was 5Ј-CGGGATCCGAAACCATGAACTTTCTGC-3Ј derived from the 5Ј end of the VEGF cDNA. The annealing temperature was 55°C. The PCR product was subcloned into the PECE expression vector (22) and expressed in DHFRϪ CHO cells as described for VEGF 162 .
Purification of VEGF 138 from serum-free medium of the VEGF 138expressing cells was achieved by chromatography on a phenyl-Sepharose column followed by ion exchange chromatography as described for VEGF 121 (24) .
The protein concentrations in various VEGFs were determined using the BioRad protein assay according to the instructions of the vendor. The VEGF content was also assessed semiquantitatively by comparing VEGF concentrations in samples containing equal amounts of protein using Western blot analysis as described previously (20) .
Cell Proliferation Assays-Human umbilical vein-derived endothelial cells were prepared from umbilical veins as described previously (25) and cultured in M199 medium supplemented with 20% fetal calf serum, vitamins, 2 mM glutamine, and antibiotics. Basic fibroblast growth factor was added to the culture every other day. For the proliferation assay, cells were plated in 24-well dishes at 20,000 cells/well. After attachment, the medium was replaced by the same medium containing 1% fetal calf serum, and various concentrations of VEGF were added. The cells received a second dose of VEGF 48 h after the beginning of the experiment, and 48 h later, the cells were trypsinized and counted in a Coulter counter.
Binding of VEGF to Extracellular Matrix-coated Dishes-Tissue culture dishes coated with extracellular matrix secreted by bovine corneal endothelial cells were prepared as described previously (26, 27) or were kindly donated by Dr. Israel Vlodavsky (Technion, Israel). Binding experiments were performed at room temperature. The extracellular matrix-coated wells were washed five times with rinse buffer (10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 0.1% Tween 20). Nonspecific sites were blocked with binding buffer (20 mM K 2 HPO 4 , 10 mM KH 2 PO 4 , 1 mM EDTA, 0.8% NaCl, 1 mg/ml bovine serum albumin, pH 7.2) for 1 h. The binding buffer was aspirated, and dishes were incubated in a final volume of 0.1 ml of binding buffer for 2 h with various amounts of VEGF forms. The dishes were then washed five times with rinse buffer. Bound VEGF was detected using an anti-VEGF monoclonal antibody that was bound to the dishes in binding buffer for 2 h. This antibody recognizes all the VEGF splice forms equally well in Western blot analysis (data not shown). Dishes were again washed five times with rinse buffer. Bound antibody was detected using anti-mouse alkaline phosphataseconjugated antibody as described previously (4) .
Alginate Bead Angiogenesis Assay-CHO-VEGF 162 and CHO-pD-CHIP11 cells were encapsulated within microspheres composed of Ca 2ϩ -alginate and a polyelectrolyte poly-L-(lysine) (4, 28) . Briefly, cells were resuspended in sodium alginate in saline (1.2% (w/v); Pronova Ultra Pure MVG) to a final ratio of 1.5 ϫ 10 6 cells/ml alginate. The suspension was sprayed through a 22-gauge needle located inside an air jet-head droplet-forming apparatus into a solution of HEPES-buffered calcium chloride (13 mM HEPES, 1.5% (w/v) CaCl 2 , pH 7.4; Sigma), where the droplets gelled for 20 min. The alginate microspheres were coated with 0.1% (w/v) poly-L-(lysine) (M r 27,000; Sigma) in saline for 12 min with gentle agitation. Capsules were washed three times in HEPES and then suspended in culture media. Clusters of alginate beads were injected subcutaneously into nude mice. The clusters of beads were removed after 6 days and examined using a dissecting microscope.
RESULTS
Human A431 Squamous Carcinoma-derived Cells Express VEGF 162 mRNA-The presence of the peptide encoded by exon 6B in VEGF 206 (2) (Fig. 1C ) indicates that this peptide may be present in additional forms of VEGF. We have used a primer derived from the 3Ј-untranslated region of the VEGF mRNA (nucleotides 827-850) to generate first-strand cDNA species from total RNA prepared from several human tumor-derived cell lines. We subsequently used a 3Ј primer corresponding to a hypothetical junction between exon 6B and exon 8 in conjunction with a 5Ј primer corresponding to the beginning of the VEGF mRNA to amplify the cDNA in order to detect exon 6B-containing VEGF splice forms differing from VEGF 206 . Using these primers, we have found that A431 squamous carcinoma cells contain a VEGF mRNA of a size corresponding to a VEGF mRNA species that contains exons 1-5, 6A, 6B, and 8 (Fig. 1A, lane 1) . No amplified cDNA could be detected in an identical control experiment in which the reverse transcriptase enzyme was omitted (Fig. 1A, lane 2) . The structure of this new VEGF cDNA was verified by sequencing, and it did indeed correspond to the expected sequence of a VEGF splice form encoding a 162-amino acid-long form of VEGF (VEGF 162 ) (Fig. 1C) .
Because the 3Ј primer used corresponded to a hypothetical exon 6B/exon 8 junction, it could perhaps have hybridized via the exon 6B matching portion of the primer to an exon 6Bcontaining cDNA such as that encoding VEGF 206 during the PCR amplification stage. Such amplification would generate the VEGF 162 cDNA, even though VEGF 162 mRNA was not present. This possibility is somewhat unlikely because the annealing temperature we used was 68°C, making annealing between VEGF 206 and the 10 exon 6B-derived bases of the primer difficult. Nevertheless, to exclude this possibility, we tried to find out whether the primer pair we used to amplify the VEGF 162 cDNA is able to amplify cDNAs encoding VEGF splice forms other than VEGF 162 . The pair of primers successfully amplified cDNAs encoding VEGF 138 (an artificial cDNA containing exons 1-5, 6B, and 8; Fig. 1C; Fig. 1B, lane 2) and VEGF 162 (Fig. 1B, lane 4) . However, we have not been able to amplify any other VEGF cDNA including the cDNA encoding VEGF 206 (Fig. 1B, lane 8) with this pair of primers under the conditions that we used to amplify the VEGF 162 cDNA derived from the A431 cells. This experiment therefore indicates that the VEGF 162 cDNA was indeed generated from a natural mRNA species encoding VEGF 162 .
Recombinant VEGF 162 Induces Proliferation of Endothelial
Cells in Vitro-To study the biological properties of VEGF 162 and to compare them with those of other VEGF splice forms, we produced recombinant VEGF 162 . The VEGF 162 cDNA was subcloned into the PECE expression vector (22) and co-transfected into CHO DHFRϪ cells (23) . Clones expressing relatively large amounts of VEGF 162 were initially isolated using a selective medium lacking nucleosides, and the integrated VEGF 162 cDNA was further amplified using methotrexate (23) . Conditioned medium from such cells, but not conditioned medium from empty vector-transfected cells, contained immunoreactive VEGF 162 ( Fig. 2A) . The VEGF 162 was partially purified using a heparin-Sepharose affinity column. It was eluted from the column with 0.8 M NaCl and used for additional experiments. At this stage, it was about 80% pure (Fig. 2B, lane 3) . VEGF 162 migrated as two bands in reduced SDS-PAGE gels, as do all the other VEGF forms (see, for example, VEGF 165 , Fig. 2B, lane 1) (4, 29). The upper band probably contains glycosylated VEGF 162 , as is the case with VEGF 165 (29) . VEGF 162 was biologically active and induced proliferation of human umbilical vein-derived endothelial cells with an ED 50 of about 10 ng/ml (Fig. 3 ). This value is somewhat lower than the ED 50 of VEGF 145 (30 ng/ml) (4), indicating that these two VEGF forms, which differ only by the presence of exon 6B in VEGF 162 , have similar biological potencies (4).
Exon 6B Inhibits the Binding of VEGF 162 to Extracellular Matrix as Compared with VEGF 145 -Although VEGF 165 and VEGF 145 display an almost identical affinity toward heparin, VEGF 165 binds less efficiently than VEGF 145 to a native basement membrane produced by corneal endothelial cells (Fig. 4B ) (4) . The presence of exon 6B is the only difference that distinguishes VEGF 162 from VEGF 145 . To find out whether exon 6B influences the ability to bind to this basement membrane, we incubated basement membrane-coated 24-well dishes with increasing concentrations of VEGF 145 or VEGF 162 as described previously using antibodies directed against VEGF to detect bound VEGF (4) . VEGF 145 bound to the basement membrane more efficiently at low concentrations, and at the maximal concentration tested (1 g/ml), the amount of VEGF 145 that bound to the basement membrane was 2-2.5-fold higher than (lane 1) were grown to confluence. The medium was changed to serum-free medium and collected 48 h later. Aliquots of 30 l were separated on a 14% SDS-PAGE gel and blotted onto nitrocellulose. VEGF was detected using polyclonal antibodies directed against VEGF as described previously (4, 20) . the amount of bound VEGF 162 (Fig. 4, A and B) . In contrast, at this concentration, VEGF 138 did not bind at all to the basement membrane despite the presence of exon 6B in this artificial VEGF form, indicating that exon 6B does not interact with extracellular matrices on its own. In that respect, VEGF 138 behaved like VEGF 121 (4). VEGF 165 was able to bind to the basement membrane as reported previously (4), although it did so less efficiently than either VEGF 145 or VEGF 162 (Fig. 4B) (4) . This result indicates that the peptide encoded by exon 6B may modulate exon 6A-mediated binding to basement membranes.
VEGF 162 Induces Angiogenesis in Vivo-To find out whether VEGF 162 induces angiogenesis, we used the alginate bead assay (4), with modifications (28) . Cells were cultured in alginate beads for 1 week to remove impurities from the alginate and to verify growth factor production and release. VEGF 162 secretion into the medium was verified by Western blot analysis (data not shown). Clusters of alginate beads were injected subcutaneously into the flanks of nude mice. After 6 days, the animals were sacrificed. The clusters of alginate beads were removed and photographed. It can be seen that blood vessels have penetrated the clusters of beads containing VEGF 162 -producing cells (Fig. 5C ) but not clusters of beads containing equal concentrations of empty vector-transfected cells (Fig. 5A) . The inner surface of the skin adjacent to the clusters of beads containing VEGF 162 -expressing cells contained a higher density of blood vessels. At places in which new blood vessels that grew into the cluster of alginate beads were ripped, bloody leaks can be seen (Fig. 5D ). The skin covering the clusters of control beads contained a lower density of blood vessels. Furthermore, the vessels were intact, and no ripped blood vessels were observed in any of the control animals (Fig. 5B) . These results indicate that VEGF 162 is able to induce angiogenesis in vivo. DISCUSSION VEGF 206 was identified as a nonsecreted VEGF form in which alternative splicing in the region of exon 6 of the VEGF mRNA resulted in a 41-amino acid insertion relative to the FIG. 3. VEGF 162 induces proliferation of human umbilical vein-derived endothelial cells. Human umbilical vein-derived endothelial cells were seeded (20,000 cells/well) and stimulated with increasing concentrations of VEGF 162 added every other day as described. After 4 days, the cells were counted in a Coulter counter. The activity is shown in comparison with the activity of a saturating concentration of VEGF 165 (5 ng/ml) done in the same experiment.
FIG. 4.
A, VEGF 145 binds more efficiently than VEGF 162 to a basement membrane produced by corneal endothelial cells. Increasing concentrations of VEGF 145 (E) or VEGF 162 (f) were bound to 24-well dishes coated with a basement membrane produced by corneal endothelial cells as described under "Experimental Procedures." The wells were then washed extensively, and bound VEGF was determined using antibodies directed against VEGF as described. Each point represents the average of three different measurements, and the error bars represent the S.D. B, comparison of the binding of various VEGF forms to basement membrane. One hundred ng of each VEGF form (1 g/ml) were bound to 24-well dishes coated with a basement membrane produced by bovine corneal endothelial cells. The wells were then washed, and bound VEGF was determined as described in A. The experiment shown is a representative experiment that was repeated three times with similar results. more widely distributed VEGF 165 . The insertion included the 24 amino acids found in VEGF 189 (2) and 17 additional amino acids. These two different portions of exon 6 have become known as exons 6A and 6B. VEGF 206 is a relatively rare form of VEGF that is not released into the conditioned medium of producing cells and is therefore difficult to study. The presence of exon 6B in VEGF 206 indicated that exon 6B may be present in additional forms and that the properties of such forms may perhaps be studied more readily. We therefore set out to look for such forms.
We have found that A431 squamous carcinoma cells contain mRNA encoding an additional exon 6B-containing VEGF form. This form is identical to VEGF 145 (4), except for the added amino acids encoded by exon 6B that lead to the production of a 162-amino acid-long VEGF form. This form may have been wrongly identified as VEGF 165 because the mass of VEGF 162 and the size of the mRNA encoding VEGF 162 closely resemble VEGF 165 . Recombinant VEGF 162 was secreted from CHO DHFRϪ cells and was biologically active as determined by endothelial cell proliferation assays and by its ability to induce angiogenesis in vivo. In these properties, it does not appear to be significantly different from VEGF 145 . VEGF 162 bound to a native basement membrane produced by corneal endothelial cells. It bound to the basement membrane less efficiently than VEGF 145 but better than VEGF 165 , which binds to such matrices relatively inefficiently, despite the substantial affinity that it displays toward heparin (4, 7). The synthetic VEGF form VEGF 138 , which contains exon 6B but lacks exon 6A, was not able to bind to this basement membrane, behaving very similarly in this respect to VEGF 121 (4) . It can therefore be concluded that exon 6B does not contribute to VEGF binding to the extracellular matrix. Rather, exon 6B seems to interfere with the interaction of exon 6A with basement membrane components, leading to a decreased extracellular matrix binding ability as compared with VEGF 145 . However, the interaction of VEGF 162 with the basement membrane is still somewhat stronger than that of VEGF 165 .
The evidence gathered in the past decade indicates that apparently insignificant differences in the properties of the VEGF splice forms have turned out to be biologically meaningful. Mice expressing only VEGF 120 or VEGF 188 develop abnormally, even if these VEGF forms are expressed at levels comparable with the expression levels of all VEGF forms put together (17) (18) (19) 30) . These changes are the result of differential affinities to heparan sulfate proteoglycans and extracellular matrix components, differential recognition of VEGF receptors, and differential susceptibility to reactive oxygen species (8, 14 -16, 31) . These differences imply that certain forms of VEGF may act more efficiently than other forms in specific microenvironments and suggest that the differential splicing of VEGF may be more tightly regulated than is currently appreciated. Some evidence supporting such tight regulation is already available. For example, it was found that progesterone selectively up-regulates the expression of VEGF 189 in decidual cells (32) .
To conclude, we have characterized a new, secreted, biologically active VEGF splice form. Whether this VEGF splice form has a biological role distinct from that of other VEGF forms is unclear at the moment, and it is not known whether there exist specific mechanisms that regulate the synthesis of the VEGF 162 mRNA. Tools that allow easy discrimination between the expression patterns of VEGF 162 and the other splice forms will have to be developed to study the in vivo expression patterns of VEGF 162 . The elucidation of these questions, as well as the design of experiments aimed at the identification of the specific biological roles of VEGF 162 , will most likely be the focus for the continuation of the research in the near future. (A and B) were embedded in alginate beads and implanted under the skin of nude mice as described. After a week, the beads were removed. The clusters of the beads (A and C) as well as the inner surface of the skin that was in contact with the beads (B and D) were photographed immediately.
FIG. 5. VEGF 162 induces angiogenesis in vivo. CHO cells expressing recombinant VEGF 162 (C and D) or CHO cells transfected with empty expression vector

